Implementation of a New Strategy to Identify HNPCC Patients
Study Details
Study Description
Brief Summary
The purpose of this study is to compare two different strategies to implement a new method to identify patients with HNPCC, which appeared cost-effective and feasible. The effectiveness, costs and feasibility of both of the implementation strategies will be assessed.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
N/A |
Detailed Description
The Radboud University Nijmegen Medical Centre developed a new method to identify patients with HNPCC. This method appeared cost-effective and feasible. Using this new method 70% of the HNPCC patients will be identified as compared to less than 30% when the current method is used. However, this new method does not implement itself; large gaps exists between best evidence and daily practice. This study will compare an intensive strategy, consisting of distribution of educational materials, education, feedback and reminders, with a minimal strategy, only consisting of distribution of a critical care pathway. The aim is to find the most cost-effective strategy to implement the new method to identify patients with HNPCC in the Netherlands.
Study Design
Outcome Measures
Primary Outcome Measures
- Efficacy of inclusion of eligible CRC-patients for MSI testing by pathologists. []
- Efficacy of referral of patients who are MSI positive to a clinical geneticist by surgeons. []
Secondary Outcome Measures
- Experiences with and acceptance of changed physician practice roles by patients and clinicians. []
- Cost efficacy of the implementation procedures. []
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Colorectal cancer before the age of 50 years
-
Second colorectal cancer at any age
-
Colorectal cancer and other HNPCC associated extracolonic cancer irrespective of age at diagnosis
-
Adenoma with high grade dysplasia diagnosed before the age of 40 years
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Jeroen Bosch Ziekenhuis | 's-Hertogenbosch | Netherlands | ||
| 2 | Meander Medisch Centrum | Amersfoort | Netherlands | ||
| 3 | Ziekenhuis Rijnstate | Arnhem | Netherlands | ||
| 4 | HagaZiekenhuis | Den Haag | Netherlands | ||
| 5 | Pathologie laboratorium voor Dordrecht | Dordrecht | Netherlands | ||
| 6 | Stichting laboratoria voor pathologische anatomie en medische microbiologie | Eindhoven | Netherlands | ||
| 7 | Laboratorium voor pathologie Oost-Nederland | Enschede | Netherlands | ||
| 8 | Martini Ziekenhuis | Groningen | Netherlands | ||
| 9 | Elkerliek Ziekenhuis | Helmond | Netherlands | ||
| 10 | Laboratorium Volksgezondheid Friesland | Leeuwarden | Netherlands | ||
| 11 | Canisius Wilhelmina Ziekenhuis | Nijmegen | Netherlands | ||
| 12 | Medisch Centrum Rijnmond Zuid | Rotterdam | Netherlands | ||
| 13 | St. Elisabeth Ziekenhuis | Tilburg | Netherlands |
Sponsors and Collaborators
- Radboud University Medical Center
- ZonMw: The Netherlands Organisation for Health Research and Development
Investigators
- Principal Investigator: Nicoline Hoogerbrugge, MD PhD, Department of Human Genetics, Radboud University Nijmegen Medical Center
- Principal Investigator: Rosella P Hermens, MSc PhD, Center of Quality of Care Research, Radboud University Nijmegen Medical Center
Study Documents (Full-Text)
None provided.More Information
Publications
- de Bruin JH, Kievit W, Ligtenberg MJ, Nagengast FM, Adang EM, Ruers TJ, Kleibeuker JH, Sijmons RH, van Krieken JH, Hoogerbrugge N. [More hereditary intestinal cancer can be detected if patients with colorectal carcinoma that are selected by the pathologist are examined for microsatellite instability]. Ned Tijdschr Geneeskd. 2005 Aug 6;149(32):1792-8. Dutch.
- Kievit W, de Bruin JH, Adang EM, Severens JL, Kleibeuker JH, Sijmons RH, Ruers TJ, Nagengast FM, Vasen HF, van Krieken JH, Ligtenberg MJ, Hoogerbrugge N. Cost effectiveness of a new strategy to identify HNPCC patients. Gut. 2005 Jan;54(1):97-102.
- MIPA-2005
- ZonMw nr. 945-14-107